三种高风险用药与老年人死亡风险的关联评估
在同时调整社会人口学、共病、器官功能、健康行为及全部高风险用药暴露后,仅多重用药(≥5种处方药)与全因死亡独立相关(HR 1.38;95%CI 1.26-1.51),而药物相互作用和潜在不适当用药未显示独立关联。
要点
- 54.3%的老年人存在至少一种高风险用药:多重用药40.0%、DDI 11.4%、PIM 37.6%。
- 充分调整后仅多重用药与死亡增加独立相关(HR 1.38;95%CI 1.26-1.51)。
- DDI与PIM在同时考虑其他高风险用药暴露后未显示独立死亡关联。
核心结论
- 在同时考虑多种高风险用药暴露时,仅多重用药与老年人全因死亡增加独立且一致相关。
- 结果提示多重用药本身的危害,可帮助将减药干预靶向最高风险患者。
研究设计与样本
- 前瞻性队列研究,纳入1999至2016年NHANES中≥65岁成人,死亡随访至2019年。
- 暴露通过基线调查时用药审核确定,主要结局为全因死亡,采用多变量Cox回归序贯调整。
主要发现
- 54.3%的参与者经历至少一种高风险用药:多重用药40.0%、DDI 11.4%、PIM 37.6%。
- 在包含全部高风险用药暴露的完全调整模型中,仅多重用药与死亡增加显著相关(HR 1.38;95%CI 1.26-1.51)。
- 按年龄和健康状态进行的敏感性与亚组分析结果总体一致。
关键数值与推荐
- 多重用药定义为使用≥5种处方药。
- DDI定义为使用两种具有≥1个主要药物相互作用的药物。
- PIM定义为使用≥1种处方潜在不适当用药。
临床怎么用
- 老年医学科应优先识别并干预使用≥5种处方药的多重用药患者以降低死亡风险。
- 减药干预可重点靶向多重用药且死亡风险最高的老年患者。
- 评估高风险用药时需同时考虑多种暴露类型,避免孤立解读DDI或PIM的危害。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Higher-risk medication use-including regimens with polypharmacy, drug-drug interactions (DDIs), and potentially inappropriate medications (PIMs)-has been linked to adverse outcomes in older adults. However, studies establishing associations between higher-risk medication use and mortality have lacked measures of organ function and considered types of higher-risk medication exposures in isolation, allowing potential confounding and overestimation of harm. METHODS: We conducted a prospective cohort study of adults aged ≥ 65 years who took part in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2016, with mortality follow-up through 2019. Our primary exposures were three types of higher-risk medication use: polypharmacy, DDIs, and PIMs. In primary analyses, these were defined, respectively, as follows: being on ≥ 5 prescription medications (polypharmacy); using two medications with ≥ 1 major DDI; and using ≥ 1 prescription PIM. Exposures were determined by medication review during the baseline survey. The primary outcome was all-cause mortality. Multivariable Cox regression models estimated mortality risk associated with each type of higher-risk medication use, sequentially adjusting for sociodemographic factors and comorbidities, organ function and health behaviors, and patterns of higher-risk medication use. RESULTS: Among 7828 eligible participants (representing 26.5 million adults), 54.3% experienced at least one type of higher-risk medication use: 40.0% had polypharmacy, 11.4% had a DDI, and 37.6% used a PIM. In fully adjusted models including all higher-risk medication exposures, only polypharmacy remained significantly associated with increased mortality (hazard ratio [HR] 1.38; 95% CI 1.26-1.51). Sensitivity and subgroup analyses by age and health status yielded generally consistent findings. CONCLUSIONS: When considering multiple types of higher-risk medication exposure, only polypharmacy was consistently and independently associated with increased mortality among older adults. These results highlight the harms of polypharmacy specifically and could help further target deprescribing interventions to the most high-risk patients.
引用
- Chaitoff A, Jungo KT, Min L, et al. Assessing Associations of Three Types of Higher-Risk Medication Use and Mortality in Older Adults. J Am Geriatr Soc. 2026. PMID: 42418735. doi:10.1111/jgs.70569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。